Literature DB >> 28070728

Sunitinib tolerance and efficacy in patients with metastatic renal cell carcinoma according to ethnic and geographic factors.

Jamal Zekri1, Saba Imtiaz2, Mubarak Al Mansour3, Waseem Darwish3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28070728     DOI： 10.1007/s11255-017-1502-5

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


× No keyword cloud information.
  9 in total

1.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  B Escudier; C Porta; M Schmidinger; F Algaba; J J Patard; V Khoo; T Eisen; A Horwich
Journal:  Ann Oncol       Date:  2014-09       Impact factor: 32.976

2.  Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?

Authors:  Mohmad Hussain Mir; Khalid Hamid Changal; Shiekh Aejaz Aziz; Gull Mohammad Bhat; Abdul Rashid Lone
Journal:  Int Urol Nephrol       Date:  2016-07-23       Impact factor: 2.370

3.  Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer.

Authors:  Y Kawai; T Osawa; K Kobayashi; R Inoue; Y Yamamoto; H Matsumoto; K Nagao; T Hara; S Sakano; S Nagamori; H Matsuyama
Journal:  Asian Pac J Cancer Prev       Date:  2015

4.  Utilization of Sunitinib for Renal Cell Cancer: an Egyptian University hospital experience.

Authors:  Ezz El Din M
Journal:  Asian Pac J Cancer Prev       Date:  2016

5.  Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia-del-Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

6.  Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

Authors:  M E Gore; C Szczylik; C Porta; S Bracarda; G A Bjarnason; S Oudard; S-H Lee; J Haanen; D Castellano; E Vrdoljak; P Schöffski; P Mainwaring; R E Hawkins; L Crinò; T M Kim; G Carteni; W E E Eberhardt; K Zhang; K Fly; E Matczak; M J Lechuga; S Hariharan; R Bukowski
Journal:  Br J Cancer       Date:  2015-06-18       Impact factor: 7.640

7.  Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma.

Authors:  Carlos H Barrios; Daniel Herchenhorn; Matías Chacón; Paula Cabrera-Galeana; Peter Sajben; Ke Zhang
Journal:  Onco Targets Ther       Date:  2016-09-23       Impact factor: 4.147

8.  Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.

Authors:  Xinan Sheng; Zhihong Chi; Chuanliang Cui; Lu Si; Siming Li; Bixia Tang; Lili Mao; Bin Lian; Xuan Wang; Xieqiao Yan; Jun Guo
Journal:  Oncotarget       Date:  2016-05-10

9.  Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience.

Authors:  Rafael Corrêa Coelho; Tomás Reinert; Franz Campos; Fábio Affonso Peixoto; Carlos Augusto de Andrade; Thalita Castro; Daniel Herchenhorn
Journal:  Int Braz J Urol       Date:  2016 Jul-Aug       Impact factor: 1.541
  9 in total
  1 in total

Review 1.  Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population.

Authors:  Ahmed Badran; Mahmoud A Elshenawy; Amgad Shahin; Ali Aljubran; Ahmed Alzahrani; Abdelmoneim Eldali; Shouki Bazarbashi
Journal:  JCO Glob Oncol       Date:  2020-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.